| Overview |
| bs-11740R-FITC |
| EBF2 Polyclonal Antibody, FITC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human EBF2 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 64641 |
| Q9HAK2 |
| Nucleus |
| COE 2; COE2; Collier Olf and EBF 2; Early B cell factor 2; EBF 2; FLJ11500; Metencephalon mesencephalnon olfactory transcription factor 1; O/E 3; O/E3; OE 3; OE3; OLF 1/EBF like 3; Transcription factor COE2; COE2_HUMAN. |
| Early B-cell factor 2 is a 575 amino acid protein belonging to the COE family of proteins, whose members are all helix-loop-helix transcription factors. EBF2 is a transcription factor which, in synergy with the Wnt-responsive LEF1/CTNNB1 pathway, activates the decoy receptor for RANKL, OPG, in osteoblasts. OPG, in turn, regulates osteoclast differentiation. Lack of EBF2 has been found to cause a small defect in the terminal differentiation of osteoblasts, along with reduced bone mass and an increase in osteoclasts. Localized to the nucleus, EBF2 forms a homodimer or a heterodimer with a related family member. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz